Figure 4 | Scientific Reports

Figure 4

From: Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC

Figure 4

c-RAF–PDE8A disruption suppresses PANC1 growth. (A) PANC1 (RTCA) growth following 60 h dose response [0.1–3 µM] with DRx-170 as (A)(i) monotherapy and (A)(ii) combination with [0.5 µM] afatinib. (A)(iii) Respective Log(µM) IC50s (N = 3). (B)(i) Day 0 brightfield images (scale bar = 100 µm) of 3D floating PANC1 spheroids and respective Day 10 images following treatment with vehicle [0.2% DMSO], DRx-150, DRx-170, afatinib or DRx-170 + afatinib. (B)(ii) Spheroid area over 10 day period and respective bar chart (iii) depicting spheroid area fold-difference vs. Day 0 (n = 5). Red arrows indicate treatment time points. MEAN ± SEM, ns, not significant; **P < 0.01; ****P < 0.0001.

Back to article page